about
Demographics, guidelines, and clinical experience in severe community-acquired pneumoniaBench-to-bedside review: Therapeutic options and issues in the management of ventilator-associated bacterial pneumoniaManagement of infections in critically ill returning travellers in the intensive care unit-II: clinical syndromes and special considerations in immunocompromised patientsManagement of infections in critically ill returning travellers in the intensive care unit-I: considerations on infection control and transmission of resistanceAdvances in antibiotic therapy in the critically illPseudomonas aeruginosa ventilator-associated pneumonia managementEuropean perspective and update on the management of nosocomial pneumonia due to methicillin-resistant Staphylococcus aureus after more than 10 years of experience with linezolidThe value of polyurethane-cuffed endotracheal tubes to reduce microaspiration and intubation-related pneumonia: a systematic review of laboratory and clinical studiesFundamentals of aerosol therapy in critical careAME evidence series 001-The Society for Translational Medicine: clinical practice guidelines for diagnosis and early identification of sepsis in the hospitalSpectrum of practice in the diagnosis of nosocomial pneumonia in patients requiring mechanical ventilation in European intensive care unitsAcute renal failure following massive mannitol infusionSevere acute respiratory infections in the postpandemic era of H1N1.Invasive candidiasis: from mycobiome to infection, therapy, and prevention.Impact of the 2009 influenza A H1N1 pandemic on invasive pneumococcal disease in adults.Influenza infection in the intensive care unit: Four years after the 2009 pandemic.Th1 and Th17 hypercytokinemia as early host response signature in severe pandemic influenza.[Pandemic influenza A in the ICU: experience in Spain and Latin America. GETGAG/SEMICYUC/(Spanish Working Group on Severe Pandemic Influenza A/SEMICYUC)].Clinical review: primary influenza viral pneumonia.Early observational research and registries during the 2009-2010 influenza A pandemic.Enteric absorption and pharmacokinetics of oseltamivir in critically ill patients with pandemic (H1N1) influenza.[Pandemic influenza A (H1N1)v in the intensive care unit: what have we learned?].Host adaptive immunity deficiency in severe pandemic influenza.Community-acquired respiratory coinfection in critically ill patients with pandemic 2009 influenza A(H1N1) virus.Severe pandemic (H1N1)v influenza A infection: report on the first deaths in Spain.Use of early corticosteroid therapy on ICU admission in patients affected by severe pandemic (H1N1)v influenza A infection.Acute kidney injury in critical ill patients affected by influenza A (H1N1) virus infection.Impact of early oseltamivir treatment on outcome in critically ill patients with 2009 pandemic influenza A.First influenza season after the 2009 pandemic influenza: report of the first 300 ICU admissions in Spain.First influenza season after the 2009 pandemic influenza: characteristics of intensive care unit admissions in adults and children in Vall d'Hebron Hospital.Direct association between pharyngeal viral secretion and host cytokine response in severe pandemic influenzaImbalanced pro- and anti-Th17 responses (IL-17/granulocyte colony-stimulating factor) predict fatal outcome in 2009 pandemic influenzaCorticosteroid therapy in patients with primary viral pneumonia due to pandemic (H1N1) 2009 influenza.Severity assessment tools in ICU patients with 2009 influenza A (H1N1) pneumonia.Interleukin-6 is a potential biomarker for severe pandemic H1N1 influenza A infection.Infections and use of antibiotics in patients admitted for severe acute pancreatitis: data from the EPIC II study.Does contemporary vancomycin dosing achieve therapeutic targets in a heterogeneous clinical cohort of critically ill patients? Data from the multinational DALI study.Pharmacokinetic variability and exposures of fluconazole, anidulafungin, and caspofungin in intensive care unit patients: Data from multinational Defining Antibiotic Levels in Intensive care unit (DALI) patients Study.Characteristics and risk factors for 28-day mortality of hospital acquired fungemias in ICUs: data from the EUROBACT studyE. coli O104:H4 outbreak and haemolytic-uraemic syndrome.
P50
Q21195015-BE41C071-58F4-46D2-B5F0-A41F8EA95005Q24811492-1C61AAD1-9307-48A6-B523-ED9B4B962D12Q26748718-1AA15479-3626-4C63-A20F-98201A0D5D89Q26748724-B573AB50-BBE7-4CDE-A74C-CC7B8D4D44EFQ26749328-B68F7567-09F6-4D0C-B04B-EF675BF99C83Q26768365-34FD0BC9-0AE1-4629-8C77-1BEB75BA5A1CQ26823518-70305437-762B-46AD-8866-10BFE7F1A62AQ27339247-C93547C0-42DF-4199-925C-4C07DBEE88A9Q28068836-B0B0B8C2-00F9-451C-B176-9D6B2D3C92FAQ28077765-13BDF040-2710-4076-8EC7-C641E5C28BBAQ28248724-69C28CEA-57CA-41B6-A3CD-B01D87D21D8CQ28341608-F6168A28-0BF7-4C43-94A0-94D3F95B4869Q30224530-0D5303A4-84A4-475B-A9C7-2AF1A0101B36Q30251428-37B1D35A-79FB-47F2-B518-D22F1A8ED3C9Q30358239-BDBD4597-5ED5-40C6-9FC8-6ADD573BEF64Q30375092-9E8CA88F-2467-4188-9A84-A532C34F3A10Q30383368-BBED1EBE-3F6D-47B7-8304-9F60A61A98D8Q30384227-8193F1CE-9D4F-4C5E-98B3-9EF6CFF79A1BQ30384602-143E8677-2744-4DFE-B714-126D87470DE7Q30384837-4AB2CCE4-07B7-452B-AD70-9BC8F7E2FBABQ30385708-67679A40-C503-4BD3-B08A-D8BC547028B7Q30387476-0739DB70-0EEB-46A0-8F18-69907709EFA4Q30393612-DA42D7A2-7C85-4CDD-8BF5-F7C37825CA7EQ30394640-3CFB0188-13DC-4C58-A1FE-7B136C3305DFQ30394861-B2347C2A-8C55-47C8-9C65-0937D3CE07EEQ30396672-8A504254-8EAE-4437-8BE4-85709001C753Q30399952-D4119707-01EC-4F81-9CC7-F69C747DE7B8Q30400544-942B5F5A-0AC1-4EBD-9B32-D970DF0C0305Q30401903-F14B3B60-D767-4160-A2ED-9A96FDF3F503Q30406125-CA476E35-C5D1-4591-8729-2ABE8FCA284EQ30406559-AF84362C-E87B-4544-8392-BB74C1A95DBEQ30408784-61C556C0-4B7C-40F5-920F-975BE1B64015Q30411669-324691B6-06EF-4DD6-9AC3-AB067AFD6DE6Q30412059-B391B259-7E0A-47F2-81C1-CF63AEE883A0Q30417745-6E73B591-25D1-47B0-AFE2-78E8E469E967Q30819025-9FCF007D-B782-451F-94EF-0700950DA98AQ30828312-3CB51C0A-FECD-4C9B-A219-7BB952D6B457Q30936281-59A4F25F-4A12-424D-A6D2-4118FE9D00F2Q31054881-EBCF9AB1-B24B-4D97-8FC3-EAA3EB076BFBQ33399183-E23011CF-255F-4286-A58F-3632C83E5D41
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
ricercatore
@it
հետազոտող
@hy
name
Jordi Rello
@ast
Jordi Rello
@en
Jordi Rello
@es
Jordi Rello
@nl
Jordi Rello
@sl
type
label
Jordi Rello
@ast
Jordi Rello
@en
Jordi Rello
@es
Jordi Rello
@nl
Jordi Rello
@sl
altLabel
Jordi Rello
@en
prefLabel
Jordi Rello
@ast
Jordi Rello
@en
Jordi Rello
@es
Jordi Rello
@nl
Jordi Rello
@sl
P1006
P214
P244
P950
P1006
P106
P1153
7102682070
P1580
P21
P213
0000 0001 0881 1922
P214
P244
P2456
P31
P496
0000-0003-0676-6210
P569
1950-01-01T00:00:00Z
P735
P7859
lccn-n00123745